Bayer lowers revenue forecasts for both drugs and weedkillers

Revenue for the crops unit will probably fall by 5% this year, as prices for the weed killer glyphosate decline, while the pharma unit’s sales will likely stay flat rather than gaining, company said

Prices have stayed stubbornly low for glyphosate-based products, including the controversial weedkiller Roundup.

Bayer has reduced its sales forecasts for its crop science and pharma divisions this year, accounting for the German company’s profit warning last month.

Revenue for the crops unit will probably fall by 5% this year, as prices for the weed killer glyphosate decline, while the pharma unit’s sales will likely stay flat rather than gaining, it said.